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INFECTIOUS COMPLICATIONS DURING INDUCTION CHEMOTHERAPY IN
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K.G. Gopakumar, T. Priyakumari, M. Kusumakumary. Regional Cancer
Centre, Trivandrum, Kerala
E-mail address: drkggopakumar@gmail.com (K.G. Gopakumar).
Background: Infections are an important cause of morbidity and mortality
for childrenwith acute myeloid leukemia (AML) and is likely related to the
intensity of their therapy resulting in repeated episodes of prolonged and
profound neutropenia.Lack of studies in the Indian scenario on this aspect
have tempted us to attempt this study.
Method: Prospective study was done in department of Pediatric oncology
with the aim of analysing the infectious complications occurring during
induction chemotherapy in children below 14years undergoing treatment
for acute myeloid leukemia. Children with newly diagnosed AML by
standard bone marrow examination and ﬂow cytometry were included.
Induction chemotherapy was with standard AML 7+3 induction protocol
after securing a central venous access (PICC line/ Broviac) in all patients. All
children received prophylactic ﬂuoroquinolones and antifungals in post
induction period. All the infectious complications occurring during the
induction chemotherapy were analysed.
Result: From the total 17 children included in the study, a total of 27 in-
duction cycles (there were 3 mortality during 1st induction and 4 children
have completed only 1st induction cycle) of chemotherapy were studied
for infectious complications. The mean age at diagnosis was 5yrs (8months
e 13years) and male: female ratio was 1:0.7. AML M5 accounted for the
majority of diagnosis (65%); the rest being AML M2 (23.4 %), AML M4 (5.8
%) and AML M1 (5.8 %). There were a total of 44 infectious events (1.6
infection/induction cycle), of which 40% (n ¼19) were microbiologically
proven. Of the total infections (n ¼ 44), pneumonitis constituted the ma-
jority (29.5%, n¼ 13) closely followed by skin infections (27.3%, n¼ 12), GIT
(20.5%, n ¼ 9), septicaemia (20.5%, n ¼ 9) and UTI (2.2%, n ¼1). There were
3 incidents of fever with unknown origin. Bacterial infections out-
numbered infections by other organisms constituting 79% (n¼15) of all the
proven infections. Among the bacterial infections, gram negative organ-
isms were isolated in most of the infections (75%, n ¼10). 3 children had
fungemia with candida parapsilosis and were appropriately treated. 3
children had varicella zoster infection and were treated with acyclovir for
14 days and other supportive care and none of the children with varicella
infection had serious complications. There was one child with incidentally
detected pinworm infestation. Therewas no Catheter related Blood stream
infection (CRBSI). All infections were acquired/ manifested during the
neutropenic period following chemotherapy. 3 children succumbed to
infectious complications during induction accounting for a mortality rate
of 17%.
Conclusion: Infectious complications are common during treatment of
AML, with children rarely escaping infection in post chemotherapy neu-
tropenic period. Prophylactic antibiotic treatment does not seem to help
much in preventing infections. Bacterial infections outnumber viral/fungal
infections with gram negative bacteria being the culprit in most events.
Strict hygienic patient care practices are crucial in prevention of infections.
Further studies aimed at assessing prevention of infections and timely
treatment would help in reduction of infection-related morbidity, and in
particular, on the reduction of bacterial infections.MM-1_V1.3
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Background: Acute promyelocytic leukemia (APML) has become a highly
curable disease withthe advent of differentiation therapy with all-trans
retinoic acid (ATRA) and Arsenic Trioxide (ATO).As reported in severallarge
multicenter trials, it has been shown that addition of ATRA to the standardchemotherapy results in overall remission rates of up to 95%and cure rates
now exceeding 80%. ATO is also highly effective in thetreatment of
APML.Studies have found that the combination of ATRA and ATO provide
excellent results and are considered standard of care by many centers. The
problems with use of this combination includes a higher risk of differen-
tiation syndrome and increased cost of treatment. In order to overcome
this cost barrier, studies from India have shown that ATO alone can provide
excellent outcomes in low risk patients and reasonably good outcomes
even in high risk patients with APML.
Method: This was a retrospective, observational study conducted in the
Pediatric Oncology Unit at KGMU, Lucknow. Case records of all newly
diagnosed APML from 01/09/2013 to 31/8/2016 were reviewed. Diagnosis
of APML was suspected on the basis of bone marrow morphology and
ﬂowcytometry and conﬁrmed by detection of PML:RARa translocation by
FISH or PCR. The treatment protocol followed at our center was either a
combination of ATRA+ATO (for patients who could afford ATRA) or ATO
alone (for those who could not afford ATRA). One or two doses of
Daunorubicinwas used during induction in childrenwho developed a high
WBC count. Clinical details, treatment and outcome details of all these
children were recorded and analyzed.
Result: In the 3yr period, 65 childrenwere diagnosed as acute myeloid
leukemia. Among them, nine patients (14%) were conﬁrmed as APML.
Median age at presentation was 96 months (Range 36-150 months). Five
children of APML presented with bleeding manifestations; six children
were high-risk (initial WBC count more than 10,000/cu.mm). While 5
patients were treated with a combination of ATRA and ATO, the remaining
4 received only ATO as the differentiation therapy. Daunorubicin was used
in 5 children. All the children tolerated there therapy well. In the 4 children
who had received ATO alone, there were no complications. In the 5 chil-
dren who received a combination of ATRA+ATO, one child had features of
differentiation syndrome (tachypnea, weight gain) which improved with
adding Dexamethasone. There were no deaths. While 7 children have
completed there therapy, 2 are currently on treatment. All the 7 children
who have completed there treatment are in molecular remission (unde-
tectable PML:RARa transcripts by PCR). None of them have relapsed. The
median follow up duration of these 7 children is 15 monnths (range 11-
36months).
Conclusion: Differentiation therapy with ATRA and ATO is highly effective
for management of APML. This therapy is very well tolerated. For parents
who cannot afford ATRA, ATO alone can be used with or without an
anthracycline depending on the total WBC counts. A small proportion of
children may develop Differentiation syndrome with the use of these
drugs, but this complication can be effectively managed with use of
dexamethasone.MM-1_V1.4
CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA (APML): EARLY
MORTALITY IS A MAJOR HINDRANCE TO AN OTHERWISE EXCELLENT
SURVIVAL: A 12-YEARS' STUDY
Vinay Munikoti 1, Deepak Bansal 1, Amita Trehan 1, Richa Jain 1, Prateek
Bhatia 1, Shano Naseem2, Neelam Varma 2. 1 Pediatric Hematology and
Oncology Unit, Advanced Pediatric Centre, Chandigarh, India; 2Department
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Background: APML is considered to have a favorable outcome. Early
mortality is however a concern and is often not highlighted.
Methodology: A retrospective study of children (<13-years) with APML
treated over a 12- years' period (2004-2015) at a single center is presented.
Chemotherapy was ATRA/anthracycline/cytarabine based (Modiﬁed
PETHEMA). Induction was followed by 3-courses of consolidation and
maintenance for 2-years. Patients were classiﬁed based on WBC as stan-
dard (<10x109/L) or high-risk (10x109/L).
Results: The cohort included 41 patients. The median age was 8-years
(range: 1e13) with anM:F of 1.8:1. Four patients did not opt for treatment.
Three patients were moribund and expired within 2-days of hospitali-
zation. Cytogenetic/molecular conﬁrmation was available in 20 (49%). In
the remaining, diagnosis was based on morphology/cyto-chemistry.
Nineteen (46.3%) patients were high-risk. The mean dose of ATRA was
